CC&Allergy

Our Product Portfolio in Vietnam

In Vietnam, STADA Pymepharco proudly owns one of the largest pharmaceutical portfolios among both international and local companies – with nearly 400 products, including around 250 Generic (Rx) medicines and close to 150 Consumer Healthcare (CHC) products.

By combining the global expertise of STADA Group with deep market insights and a strong local legacy, STADA Pymepharco continuously expands its portfolio to deliver German-standard healthcare solutions – meeting the growing and diverse needs of domestic consumers while supporting a long-term strategy for sustainable export growth.

Tra cứu hoạt chất

Active Pharmaceutical Ingredients

STADA Pymepharco has a strong competitive edge in the Generics segment, with a portfolio of nearly 250 products covering a broad range of key therapeutic areas in modern medicine: antibiotics, anti-inflammatory, gastrointestinal, cardiovascular, metabolic, diabetes treatments, and many more.

All products are developed based on extensive research and strictly comply with the stringent EU-GMP and WHO-GMP standards, ensuring bioequivalence, treatment efficacy, and patient safety in every product. Our Generics portfolio are trusted by healthcare professionals across Vietnam and play a vital role in improving treatment accessibility and reducing the cost burden for patients.